bictegravir/emtricitabine/tenofovir vs cidofovir
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of bictegravir/emtricitabine/tenofovir and cidofovir. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] .
Biktarvy
Vistide
Biktarvy is a complete HIV-1 treatment for adults and children who weigh at least 31 pounds. It combines three medicines into one tablet to help control the virus.
Cidofovir injection is an antiviral medicine. It is used to treat CMV retinitis, an eye infection, in people with AIDS.
Biktarvy treats Human Immunodeficiency Virus type 1 (HIV-1) in adults and children weighing at least 31 pounds. It can be used if you have never taken HIV medicine before. It can also replace your current HIV medicine if your virus is under control and you have no resistance to Biktarvy's components.
Cidofovir treats CMV retinitis in people who have AIDS. CMV retinitis is an infection in the eye that can cause vision problems. This medicine has not been proven to work for other CMV infections or in people without HIV.
Biktarvy contains three drugs that each block HIV in different ways. Bictegravir stops HIV from inserting its DNA into your cells. Emtricitabine and tenofovir alafenamide interfere with an enzyme HIV needs to make copies of itself.
Cidofovir stops the CMV virus from making copies of itself. It does this by blocking a key enzyme the virus needs to reproduce its DNA. This helps to reduce the amount of virus in your body.
- • Diarrhea
- • Nausea
- • Headache
- • Kidney problems
- • Lowered white blood cell count
- • Decreased eye pressure
- • Inflammation inside the eye
No adverse event reports.
No adverse event reports.
If you have both HIV and hepatitis B, stopping Biktarvy can cause your hepatitis B to suddenly get worse. Your doctor will need to monitor your liver closely for several months after you stop taking Biktarvy. You may need to take medicine for hepatitis B.
Cidofovir can cause serious kidney damage, possibly leading to death. To reduce this risk, you must receive IV fluids and take probenecid pills with each dose. Your kidney function and white blood cell counts will be checked regularly. This drug can also cause birth defects and cancer, based on animal studies. It is only for treating CMV retinitis in AIDS patients.
There is a pregnancy registry to track outcomes in women who take Biktarvy during pregnancy. Talk to your doctor about the risks and benefits of taking Biktarvy if you are pregnant or planning to become pregnant. There is not enough data to assess the risk of major birth defects.
Cidofovir may cause harm to an unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if cidofovir passes into breast milk, so talk to your doctor if you are breastfeeding.
Also Compare, Nearby Drugs
Compare bictegravir/emtricitabine/tenofovir with
How to Read This bictegravir/emtricitabine/tenofovir vs cidofovir Comparison
bictegravir/emtricitabine/tenofovir is classified in the Integrase Inhibitor / NRTI Combination drug class, while cidofovir sits within the Antiviral (Nucleotide Analog) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, bictegravir/emtricitabine/tenofovir has 0 submissions while cidofovir has 0. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to both drugs are removed from the body through the same pathway in the kidneys. taking them together may cause the drugs to build up in your system.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for bictegravir/emtricitabine/tenofovir or cidofovir.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.